Cardiology

Clinical decisions on LDL-C management currently rely on a measure at one time point, typically middle age. A new study suggests burden begins early and so should assessment.

A new AHA scientific statement suggests metabolic surgery and weight-loss medications may reduce the long-term effects of obesity-related hypertension.

New hypertension research looks at stress hormones in early disease, the Quadpill as first Rx, tight BP control for older adults--for a start. We recap 8 new studies.

CCTA identified atherosclerosis in >40% of middle-aged adults without known coronary heart disease, report Swedish investigators; significant stenosis was found in another 5.2%.

Dapagliflozin adds substantial improvements in symptoms, exercise function to demonstrated disease-modifying properties for patients with HFpEF.

Identifying white coat and masked hypertension is essential for prevention of CV morbidity and mortality. Review the ACC/AHA recommendations on how to detect and manage.

Each doubling of levels of 4 stress hormones was associated with a 21-31% increase in risk of developing hypertension over a median 6.5-year follow-up.

New research suggests frequent cannabis use can raise the risk of myocardial infarction in adults younger than 45 years.

Patients with HIV had a 14% higher risk of sudden cardiac death than those without HIV, according to a large analysis of US veterans.

ESC Congress 2021: Results from the largest trial of its kind suggest that flu vaccination should be part of in-hospital treatment after myocardial infarction.

Aggressive control of systolic BP in adults aged 60 to 80 years significantly reduced CV risk, adding to evidence from the pivotal SPRINT trial in support of tight BP control.

Substituting regular salt with low-sodium alternative was found to reduce the risk of stroke, major cardiovascular events, and death in a new study presented at ESC Congress 2021.

Finerenone, in patients with mild-to-moderate renal disease and T2D, reduced CV event risk by 13% and risk for a composite renal event by 23%, study authors reported at ESC 2021.

In a pooled analysis of 2 key clinical trials, empagliflozin was beneficial in patients with heart failure with a reduced and preserved ejection fraction.

Empagliflozin in patients with HFpEF reduced by 21% the risk of cardiovascular death or heart failure hospitalization across all prespecified subgroups, including those with/without diabetes.

The ESC Congress 2021, Aug 27-30, 2021, is here. For primary care, we highlight the "Hot Lines" clinical trial presentations where new data from novel trials will premier.

Consuming saturated fat from meat may be associated with a higher risk of CVD than other food sources, according to a new study presented at ESC Congress 2021.

Periodontitis was associated with an increased risk for CVD, particularly among patients with past myocardial infarction, in a new study being presented at ESC Congress 2021.

New findings being presented at ESC Congress 2021 highlight the need for smoking cessation services tailored to the specific needs of women.

With the post-LER PAD indication, rivaroxaban becomes the only anticoagulant in 2 decades to demonstrate safety and efficacy in the high-risk population.

Younger adults with myocardial infarction are more likely to be smokers, obese, and have hypertension than their peers, suggests a new study being presented at the ESC Congress 2021.

COVID-19 patients after just 5 days or less in the hospital report new or worsened symptoms, impaired daily function, and significant financial loss.

A new study suggests that walking even 3 or 4 hours a week may reduce long-term mortality from any cause in patients with a history of stroke.

Delaying or forfeiting care for HF significantly increased future health care costs, a finding at odds, say study authors, with the inability to afford regular treatment.

A recent meta-analysis found that consuming up to 105 g of alcohol a week was associated with lower risks of cardiovascular events and mortality among adults with CVD.